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Abstract There is evidence that reactive oxygen species
play a causal role in auto-immune diseases, such as
rheumatoid arthritis (RA). Despite the supporting evidence
for a beneficial effect of antioxidants on clinical character-
istics of RA, the right balance for optimal effectiveness of
antioxidants is largely unknown. To determine the potential
beneficial effects of an antioxidant intervention on clinical
parameters for RA, an open pilot study was designed. Eight
non-smoking female patients with rheumatoid factor + RA
and a Disease Activity Score (DAS 28) higher than 2.5
were enrolled in the study. Patients had to be receiving
stable non-steroidal anti-inflammatory drug treatment and/
or ‘second line’ medication for at least 3 months. The pilot
group consumed 20 g of antioxidant-enriched spread daily
during a period of 10 weeks. The intervention was stopped
after 10 weeks and was followed by a ‘wash-out’ period of
4 weeks. At t=0, t=10 weeks and t=14 weeks, patients’
condition was assessed by means of DAS. In addition,
standard laboratory analyses were performed, and blood-
samples for antioxidants were taken. The antioxidant-
enriched spread was well tolerated. All laboratory measures
of inflammatory activity and oxidative modification were
generally unchanged. However, the number of swollen and
painful joints were significantly decreased and general
health significantly increased, as reflected by a significantly
improved (1.6) DAS at t=10 weeks. The antioxidant effect
was considered beneficial as, compared to the scores at t=0,
the DAS significantly reduced at t=10 weeks. Increase of
the DAS (0.7) after the “wash-out period” at t=14
confirmed a causal relation between changes in clinical
condition and antioxidants. This open pilot study aimed to
assess the clinical relevance of an antioxidant intervention
as a first step in assessing potential beneficial effects of
antioxidants on rheumatoid arthritis. These conclusions
need to be validated in a larger controlled study population.
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Introduction
In spite of the great advances that have been made in the
development of new drugs for the treatment of patients with
rheumatoid arthritis (RA), many patients are interested in
alternative treatments like dietary therapy. Although the
aetiology of rheumatoid arthritis is still unknown, the
inflammation resulting from the immunological reaction is
quite well described. It is known that neutrophil granulo-
cytes, macrophages and lymphocytes are activated, and that
reactive oxygen and nitrogen species (RS) are produced [1,
2]. These RS can react with lipid, protein and nucleic acids
and are thought to be of importance for the aetiology and
chronicity of the inflammatory rheumatic diseases [3, 4].
One approach to counteract this oxidative stress situation is
the use of antioxidants as therapeutic agents. There is some
evidence for a positive effect of antioxidants on clinical
symptoms of RA [5, 6]. However, this evidence is weak,
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antioxidant doses or combinations is lacking The interven-
tion studies that have been conducted have tested vitamin E
exclusively [6, 7].
Against this background, an open (uncontrolled) pilot
study was designed to assess if effects of antioxidants on
the clinical parameters of patients with RA could be
confirmed and if these effects would associate with changes
in a selected number of molecular markers related to human
antioxidant defence system status. Further, a mix of anti-
oxidants was to be tested rather than a single high-dosed
compound.
Materials and methods
The open study was approved by the ethical committee.
Eight patients with rheumatoid factor + RA, as defined by
the ARA revised criteria were enrolled in the study. To
avoid influences of gender, only female patients participat-
ed. Inflammatory disease activity was defined as a Disease
Activity Score (DAS) higher than 2.5. Inclusion criteria
included non-smoking and no serious co-morbidity.
Patients had to be receiving stable non-steroidal anti-
inflammatory drug (NSAID) treatment and/or ‘second line’
medication for at least 3 months. Those taking antioxidant
supplements were excluded from the study. During a period
of 10 weeks, patients consumed 20 g of antioxidant-
enriched margarine daily. The spread contained a mix of
a-tocopherol (400 mg), lycopene (10 mg), palm oil
carotenoids (5 mg; mainly α-carotene) and lutein (10 mg).
Further, patients received vitamin C (200 mg daily) as a
supplement.
The intervention of 10 weeks was followed by a ‘wash-
out’ period of 4 weeks. At t=0,t=5 weeks, t=10 weeks and
t=14 weeks, patients’ condition was assessed by means of
morning stiffness, visual analogue scale pain, general health
score and DAS 28-score (including the following parame-
ters: pain, swelling of joints, erythrocyte sedimentation rate
(ESR), general feeling of well-being). At t=0, t=10 weeks
and at t=14 weeks, blood was collected, and standard
clinical laboratory analyses (ESR, C-reactive protein,
hemoglobin, leucocytes, thrombocytes, serum values of
creatinine and transaminases) were performed. In addition,
blood antioxidant status and markers of antioxidant
capacity [ferric reducing ability of plasma (FRAP)] and
oxidative stress (8-epi F2-isoprostane) levels were deter-
mined. Determination of vitamin A, not present in the
spread, was used as a control. Serum was collected
immediately after blood sampling and stored in liquid
nitrogen. The potential antioxidant effect was defined as
beneficial if the DAS score would significantly improve
>1.2 at t=10 weeks as compared to the scores at t=0.Att=
14 weeks, a ‘wash-out” effect was assessed using the same
parameters. Return of the clinical condition of the pilot
group to that at t=0 may indicate a causal relation between
changes in clinical condition and antioxidant intake,
although a placebo-controlled intervention would be better
required for this assessment.
Statistical analyses were done using a paired t test.
Results
The antioxidant-enriched spread was well tolerated. None
of the patients withdrew from the study because of adverse
reactions. The number of swollen and painful joints were
significantly decreased, and general health significantly
increased at t=10 weeks. This was shown by a significantly
decreased DAS (−1.6) at 10 weeks. After the “wash-out
period”, the DAS score was increased again by 0.6 (Figs. 1
and 2).
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activity were relatively unchanged. Levels of plasma
vitamin E, lutein, lycopene and alpha-carotene were
significantly increased at 10 weeks. No significant changes
were seen in vitamin A and vitamin C levels (Fig. 3).
Markers of antioxidant capacity and oxidative stress
displayed trends for differences, but none of these reached
statistical significance (Fig. 4).
Discussion
This pilot study was conducted to obtain some first
indications for potential beneficial effects of an antioxidant
intervention on clinically relevant parameters for rheuma-
toid arthritis. In our present study, a significant reduction in
Disease Activity Score (DAS) was observed following
antioxidant intervention of 10 weeks. This was accompa-
nied by significant increases in blood levels of antioxidants
administered. The reduction of DAS is remarkable as all
patients had an active (high initial mean DAS of 5.8)
longstanding disease and had tried all kinds of disease-
modifying anti-rheumatic drugs, including combination
therapy. The unchanged level of vitamin A, not present in
the spread, reinforces the significance of the increased
levels of the blood antioxidant status. As NSAIDs can
influence the absorption of vitamin C, this could explain the
non-significant changes of the serum concentration of this
antioxidant.
A limited number of clinical intervention studies is
available which support the therapeutic or prophylactic
activity of antioxidants in the pathogenesis of RA. These
studies were all conducted with an oral intake of 1,200 mg/
day of vitamin E. Edmonds et al. [6] reported that the
antioxidant a-tocopherol significantly reduced pain param-
eters in a placebo-controlled double-blind trial following a
3-week supplementation period. Results from a randomised
double-blind parallel group comparison study with a-
tocopherol and diclophenac showed that the clinical
parameters assessed, e.g. morning stiffness, Ritchie joint
index, grip strength and pain, were significantly reduced by
vitamin E, with similar effectivity and less side effects as
compared to regular drug therapy by diclofenac [7]. Results
from other intervention studies have generally been in line
with these observations [8, 9].
In our study, not only the effect of vitamin E on the
inflammatory response and clinical symptoms was evaluat-
ed but also the interactions with bioavailable natural
antioxidants such as carotenoids, vitamin C and others. In
view of the limited number of controlled studies, the
supporting evidence for beneficial effects of antioxidants
on clinical characteristics of rheumatoid arthritis may be
considered limited but promising. Another point is that the
potential mechanism of action of antioxidants in rheuma-
toid arthritis needs further attention. The aspect of damage
by RS and loss of critical functions can be analysed by use
of ‘molecular markers’. These markers may include
antioxidant status, products which arise as a consequence
of oxidative damage to lipid, protein and DNA and tissue
damage (as assessed by lactic dehydrogenase release) or
cytokine levels (cq anti-TNFα).
Although markers are very informative from a mecha-
nistic point of view, a drawback is that none of them has
been validated against clinical conditions of patients with
RA. In this study, a trend for reduced levels of measures of
antioxidant capacity and of ‘footprints’ of oxidative stress
was observed, e.g. statistically non-significant increase in
FRAP and reduction in F2-isoprostane levels. Furthermore,
these markers showed a trend for correlation with clinical
conditions. The data indicate that statistically significant
effects may be observed when the number of patients
enrolled is increased.
This open pilot study therefore should be viewed as a first
step in assessing potential beneficial effects of the antiox-
idants tested on rheumatoid arthritis. The data indicate there
may be potential in using mixes of antioxidants in the
treatment of RA alongside drug treatment so that drug dosage
may be reduced while hopefully retaining efficacy. Further,
multi-drug/antioxidant therapy could be used to reduce drug
dose and thus side effects of treatment.
In conclusion, our present pilot study indicated that
intervention with antioxidant-enriched margarine in RA
results in consistent and significant relief of clinical
symptoms. Furthermore, increases in blood antioxidant
status and indications for effects on oxidative stress markers
were observed. These data are promising and indicate need
for a double-blind, placebo-controlled randomised human
trial to establish effect and demonstrate causality.
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